Somatostatin analogs and radiopeptides in cancer therapy (Q34972896)

5 August 2017

1 reference

title

Somatostatin analogs and radiopeptides in cancer therapy (English)

1 reference

5 August 2017

Sylvie Froidevaux

1 reference

5 August 2017

Alex N Eberle

series ordinal

1 reference

5 August 2017

language of work or name

1 reference

1 January 2002

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

161-183

1 reference

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

5 August 2017

cites work

1 reference

Distribution, ontogeny and ultrastructure of somatostatin immunoreactive cells in the pancreas and gut

21 January 2018

1 reference

Somatostatin and its receptor family

21 January 2018

1 reference

Antiproliferative effect of somatostatin and analogs

21 January 2018

1 reference

Somatostatin: the neuroendocrine story

21 January 2018

1 reference

A physiologic role for somatostatin 28 as a regulator of insulin secretion

21 January 2018

1 reference

Expression cloning of a rat brain somatostatin receptor cDNA

21 January 2018

1 reference

Cloning and expression of a novel mouse somatostatin receptor (SSTR2B).

21 January 2018

1 reference

Cloning and characterization of a fourth human somatostatin receptor

21 January 2018

1 reference

Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4

21 January 2018

1 reference

Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype

21 January 2018

1 reference

Cloning of the gene encoding human somatostatin receptor 2: sequence analysis of the 5'-flanking promoter region

21 January 2018

1 reference

Cloning of the mouse SSTR5 gene

21 January 2018

1 reference

Molecular cloning and functional characterization of a rat somatostatin sst2(b) receptor splice variant

21 January 2018

1 reference

Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor

21 January 2018

1 reference

Molecular biology of somatostatin receptor subtypes

21 January 2018

1 reference

Somatostatin receptor subtype gene expression in human endocrine gastroentero‐pancreatic tumours

21 January 2018

1 reference

Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer?

21 January 2018

1 reference

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

21 January 2018

1 reference

Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid

21 January 2018

1 reference

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

21 January 2018

1 reference

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours

21 January 2018

1 reference

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors

21 January 2018

1 reference

Distribution and functional significance of somatostatin receptors in malignant melanoma.

21 January 2018

1 reference

Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers

21 January 2018

1 reference

Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).

21 January 2018

1 reference

Binding properties of somatostatin receptor subtypes

21 January 2018

1 reference

Molecular pharmacology of somatostatin receptor subtypes

21 January 2018

1 reference

Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry

21 January 2018

1 reference

Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.

21 January 2018

1 reference

Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation

21 January 2018

1 reference

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

21 January 2018

1 reference

Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A).

21 January 2018

1 reference

Endocytosis of the rat somatostatin receptors: subtype discrimination, ligand specificity, and delineation of carboxy-terminal positive and negative sequence motifs

21 January 2018

1 reference

Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization

21 January 2018

1 reference

Somatostatin receptor desensitization in NG108-15 cells. A consequence of receptor sequestration.

21 January 2018

1 reference

Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes

21 January 2018

1 reference

Distribution of somatostatin receptors in RINm5F insulinoma cells

21 January 2018

1 reference

Somatostatin receptor manipulation

21 January 2018

1 reference

17 beta-estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells

21 January 2018

1 reference

Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells

21 January 2018

1 reference

Inactivation of somatostatin (GH‐RIH) and its analogs by crude and partially purified rat brain extracts

21 January 2018

1 reference

Structure-function relationships of somatostatin analogs

21 January 2018

1 reference

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

21 January 2018

1 reference

Somatostatin and somatostatin analogues in oncology

21 January 2018

1 reference

Synthesis and biological activity of highly potent octapeptide analogs of somatostatin

21 January 2018

1 reference

Superactive octapeptide somatostatin analogs containing tryptophan at position 1.

21 January 2018

1 reference

Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.

21 January 2018

1 reference

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

21 January 2018

1 reference

The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth

21 January 2018

1 reference

Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours

21 January 2018

1 reference

The role of somatostatin agonistic analogs in the treatment of acromegaly

21 January 2018

1 reference

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly

21 January 2018

1 reference

Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995.

21 January 2018

1 reference

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

21 January 2018

1 reference

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

21 January 2018

1 reference

Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines

21 January 2018

1 reference

High affinity binding of [125I-Tyr11]somatostatin-14 to human small cell lung carcinoma (NCI-H69).

21 January 2018

1 reference

Somatostatin receptor expression in lung cancer

21 January 2018

1 reference

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer

21 January 2018

1 reference

Somatostatin Analogue Phase I Trials in Neuroendocrine Neoplasms

21 January 2018

1 reference

Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer.

21 January 2018

1 reference

21 January 2018

1 reference

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook

21 January 2018

1 reference

Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).

21 January 2018

1 reference

Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells

21 January 2018

1 reference

Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture

21 January 2018

1 reference

The effects of the somatostatin analog octreotide on angiogenesis in vitro.

21 January 2018

1 reference

Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action

21 January 2018

1 reference

Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients

21 January 2018

1 reference

Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype

21 January 2018

1 reference

Effect of the neuropeptides beta-MSH, neurotensin, NPY, PHI, somatostatin and substance P on proliferation of lymphocytes in vitro

21 January 2018

1 reference

Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity

21 January 2018

1 reference

Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.

21 January 2018

1 reference

Protein tyrosine phosphatases in signal transduction.

21 January 2018

1 reference

Co-purification of a protein tyrosine phosphatase with activated somatostatin receptors from rat pancreatic acinar membranes

21 January 2018

1 reference

The Tyrosine Phosphatase SHP-1 Associates with the sst2 Somatostatin Receptor and Is an Essential Component of sst2-mediated Inhibitory Growth Signaling

21 January 2018

1 reference

ActivationIn Vitroof Somatostatin Receptor Subtypes 2, 3, or 4 Stimulates Protein Tyrosine Phosphatase Activity in Membranes from Transfected Ras-Transformed NIH 3T3 Cells: Coexpression with Catalytically Inactive SHP-2 Blocks Responsiveness

21 January 2018

1 reference

Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells

21 January 2018

1 reference

Induction of Apoptosis in Neuroendocrine Tumors of the Digestive System During Treatment with Somatostatin Analogs

21 January 2018

1 reference

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation

21 January 2018

1 reference

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

21 January 2018

1 reference

Technetium-99m direct radiolabeling of lanreotide: a somatostatin analog

21 January 2018

1 reference

Technetium-99m labelling of glycosylated somatostatin-14.

21 January 2018

1 reference

Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model

21 January 2018

1 reference

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

21 January 2018

1 reference

Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.

21 January 2018

1 reference

Somatostatin receptor scintigraphy using [ 111 In-DTPA 0 ]RC-160 in humans: a comparison with [ 111 In-DTPA 0 ]octreotide

21 January 2018

1 reference

Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours

21 January 2018

1 reference

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue

21 January 2018

1 reference

Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.

21 January 2018

1 reference

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

21 January 2018

1 reference

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

21 January 2018

1 reference

Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.

21 January 2018

1 reference

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice

21 January 2018

1 reference

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

21 January 2018

1 reference

Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

21 January 2018

1 reference

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/BIP.10256

1 reference

5 August 2017

1 reference